“The results make it clear that there is good hope that treatment of [Alzheimer’s] pathology in the preclinical stages of pathology may be effective at slowing or preventing disease onset ...

Alzheimer's disease is one of the most common causes of memory loss and dementia. A hallmark of the disease is the buildup of sticky protein clumps in the brain, known as amyloid-beta plaques.

other health issues New Alzheimer's drug offered to Summit Township man. 'It does give us hope' Five years later: COVID-19 no longer public emergency but still affects Erie's health care Anyone ...

The authors concede that the study is small and limited by the open-label design, saying the funding ... result in false hope for patients with inherited forms of Alzheimer's and their families.

In its current form, the diagnosis of Alzheimer’s disease requires expensive neurological tests, brain scanning, blood analysis, and more. There is no single, or definitive, biomarker test.

For the first time, scientists say they have evidence that a drug might delay the onset of Alzheimer’s symptoms in people who are genetically predisposed to getting the disease in their 40s or 50s.